INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA

被引：0
|
作者：
Cooper, Nichola [1 ]
Jansen, A. J. Gerard [2 ]
Mayer, Jiri [3 ]
Tarantino, Michael D. [4 ]
Diab, Remco [5 ]
Ward, Brad [6 ]
Daak, Ahmed [6 ]
Kuter, David J. [7 ]
机构：
[1] Hammersmith Hosp, London, England
[2] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Masaryk Univ Hosp, Brno, Czech Republic
[4] Univ Illinois, Bleeding & Clotting Disorders Inst, Coll Med Peoria, Peoria, IL USA
[5] Sanofi, Rotkreuz LU, Vernier, Switzerland
[6] Sanofi, Cambridge, MA USA
[7] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomised, Placebo-controlled, Phase 2 Study
    Bojanowski, J.
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E. C.
    Syed, S.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP69 - NP70
  • [32] Safety/efficacy of evobrutinib, a Bruton's tyrosine kinase inhibitor, 2.5 years into Phase II MS open-label extension
    Montalban, X.
    Wolinsky, J.
    Arnold, D.
    Weber, M.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Tomic, D.
    Martin, E.
    Holmberg, K.
    Guehring, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 223 - 223
  • [33] Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
    Shah, Nirav N.
    Wang, Michael
    Roeker, Lindsey E.
    Patel, Krish
    Woyach, Jennifer A.
    Wierda, William G.
    Ujjani, Chaitra S.
    Eyre, Toby A.
    Zinzani, Pier Luigi
    Alencar, Alvaro J.
    Ghia, Paolo
    Lamanna, Nicole
    Hoffmann, Marc S.
    Patel, Manish R.
    Flinn, Ian
    Gerson, James N.
    Ma, Shuo
    Coombs, Catherine C.
    Cheah, Chan Y.
    Lech-Maranda, Ewa
    Fakhri, Bita
    Kim, Won Seog
    Barve, Minal A.
    Cohen, Jonathon B.
    Jurczak, Wojciech
    Munir, Talha
    Thompson, Meghan C.
    Tsai, Donald E.
    Bao, Katherine
    Cangemi, Nicholas A.
    Kherani, Jennifer F.
    Walgren, Richard A.
    Han, Hongmei
    Ruppert, Amy S.
    Brown, Jennifer R.
    HAEMATOLOGICA, 2025, 110 (01) : 92 - 102
  • [34] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [35] Preliminary safety and efficacy of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL).
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, David M.
    Lozanski, Gerard
    Hutchinson, Terri
    Sexton, Jennifer L.
    Harris, Pamela Jo
    Grever, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB IS ACTIVE AND TOLERABLE IN PATIENTS WITH RELAPSED/REFRACTORY CLL, INTERIM RESULTS OF A PHASE IB/II STUDY
    Brown, J.
    Barrientos, J.
    Flinn, I.
    Barr, P.
    Burger, J.
    Navarro, T.
    James, D.
    Hedrick, E.
    Friedberg, J.
    O'Brien, S.
    HAEMATOLOGICA, 2012, 97 : 218 - 218
  • [37] Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
    Isenberg, David
    Furie, Richard
    Jones, Nicholas
    Guibord, Pascal
    Galanter, Joshua
    Lee, Chin
    McGregor, Anna
    Toth, Balazs
    Rae, Julie
    Hwang, Olivia
    Miranda, Pedro
    de Souza, Viviane
    Jaller-Raad, Juan
    Fernandes, Anna Maura
    Garcia Salinas, Rodrigo
    Chinn, Leslie
    Townsend, Michael
    Morimoto, Alyssa
    Tuckwell, Katie
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [38] Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
    Shi, Wenyu
    Ben, Yu
    Zhang, Yaping
    Li, Jianyong
    BLOOD, 2022, 140 : 12121 - 12121
  • [39] Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma
    Huang, Hong-Hui
    Hou, Jian
    Zhang, Yang-Ming
    Zhou, Yu-Bo
    Jia, Li
    Nan, Fa-Jun
    BLOOD, 2019, 134
  • [40] Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and NonCovalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase
    Woyach, Jennifer A.
    Stephens, Deborah M.
    Brander, Danielle M.
    Kittai, Adam S.
    Hu, Boyu
    Sitlinger, Andrea
    Curran, Emily K.
    Tan, Fenlai
    Chen, Yi
    Anthony, Stephen P.
    Chen, Yu
    Byrd, John C.
    BLOOD, 2023, 142
12345